Phyto-anti-estrogens are potential selective modifiers of biological reactions in breast cancer


Cite item

Full Text

Abstract

The review analyzes up-to-date information about specific characteristics of anti-estrogen therapeutic agents with different mechanisms of action with regard to present knowledge of endocrine therapy for estrogen-positive breast cancer (ER+ BC). The paper presents some agents for anti-estrogen therapy of breast cancer - aromatase inhibitors and selective modifiers of biological reactions (SMBR) and their mechanisms of anti-proliferative action. The authors describe significant therapeutic and side effects as well as different options for anti-estrogen combinations. Special emphasis is made on national herbal estrogens/anti-estrogens that have no toxicity associated with the well-known SMBRs. The review presents the structure and characteristics of a perspective phyto-anti-estrogen sekoizolaricirezinol (SEKO), which demonstrated significant anti-proliferative activity with no pro-estrogen action in the in vivo models of ER+ BC.

About the authors

Juliya A. Borisova

N.N. Blokhin Russian Cancer Research Center

Email: gsmir53@yandex.ru
Junior researcher of the Laboratory for combination therapy of tumors of the Research Institute of Experimental Diagnostics and Therapy of Tumors Moscow, 115478, Russian Federation

G. B Smirnova

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

I. Zh Shubina

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

Z. S Shprakh

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

E. M Treshchalina

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

References

  1. Гарин А. М. Эндокринная терапия и гормонозависимые опухоли. М.-Тверь: ООО «Издательство Триада»; 2005.
  2. Beatson G.Т. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896; 2: 104-7.
  3. Boyd S. On oophorectomy in cancer in the breast. Br. Med. J. 1900; 1 (2): 1161-7.
  4. Fracchia A.A., Farrow J.H., DePalo A.J. et al. Castration for primary inoperable or reccurent breast carcinoma. Surg. Gynec. Obstetr. 1969;129: 1226-34.
  5. Кореневский Л.И., Ищенко М.П. Клиническая онкология. Киев; 1965; Вып. 1: 104-10.
  6. Featherstone C., Harnet A.N. Ultrasuond localization of the ovaries for radiation - induced of ovarian ablation. Clin. Oncol. (R. Coll. Radiol.). 1999; 11 (6): 393-7.
  7. Моисеенко В.М., Семиглазов В.В., Тюляндин С.А. Современное лекарственное лечение местно-распространенного и метастатического рака молочной железы. СПб.: Грифон; 1997.
  8. Семиглазов В.Ф., Семиглазов В.В., Иванов В.Г. и др. Гормонотерапия операбельного рака молочноы железы. Медицинский академический журнал. 2003; 3 (3): 79-87.
  9. Yip C. H., Smith R. A., Anderson B. O. et al. Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer. 2008; 113(8): 2244-56.
  10. Ulrich P. Testosterone (hormone male) etson role possitible la traitement de certain cancer du sein. Acta Int. Cancer. 1939; 4: 347.
  11. Haddow A., Watkinson J.M., Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. Br. Med. J. 1944; 2: 393-8.
  12. Переводчикова Н.И., Горбунова В.А. Руководство по химиотерапии опухолевых заболеваний. 4-е изд. М.: Практическая медицина; 2015.
  13. Майоров М.В. Эстрогены - старые приятели и новые знакомые. Провизор. 2005; (5): 27-30.
  14. Abplanalp W., Scheiber M.D., Moon K., Kessel B., Liu J.H., Subbiah M.T. Evidence for the role of high density lipoproteins in mediating the antioxidant effect of estrogens. Eur. J. Endocrinol. 2000; 142 (1): 79-83.
  15. Yue W., Santen R., Wang J.-P. et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J. Steroid Biochem. Mol. Biol. 2003; 86 (3-5): 477-86.
  16. Preston-Martin S., Pike M.C., Ross R.K. et al. Increased cell division as a cause of human cancer. Cancer Res. 1990; 50 (23): 7415-21.
  17. Fishman J. Aromatic hydroxylation of estrogens. Annu. Rev. Physiol.1983; 45 (1): 61-72.
  18. Онкогинекология / Под ред. З.Ш. Гилязутдиновой, М.К. Михайлова. М.: МЕДпресс; 2000.
  19. Заридзе Д.Г. Эпидемиология и скрининг рака молочной железы. Вопросы онкологии. 2002; 48 (4-5): 489-94.
  20. Wilcken N., Hornbuckle J., Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst. Rev. 2003; 83 (8): 411-7.
  21. Brankoviс-Magiс M, Jankoviсh R, Neskovich-Konstantinovich Z et al. Progesterone receptor status of breast cancer metastases. J. Cancer Res. Clin. Oncol. 2002; 128: 55-60.
  22. McGuire W.L., Carbone P.P., Volmer E.P. et al. Estrogen Receptors in Human Breast Cancer. New York: Raven Pressl; 1975.
  23. Jonat W., Zoladex T.M. CMF as adjuvant therapy in pre-/perimenopausal node-positive breast cancer: first efficacy results from ZEBRA Study. Eur. J. Cancer. 2000; 36 (5): 67-132.
  24. Fournier D., Poirier D. Estradiol dimers as a new class of steroid sulfatase reversible inhibitors. Bioorg. Med. Chem. Lett. 2009; 19 (3): 693-6.
  25. Buzdar A.U. Role of aromatase inhibitors in advanced breast cancer. Endocrine-Related Cancer. 1999; 6: 219-25.
  26. Poirier D. New cancer drugs targeting the biosynthesis of estrogens and androgens. Drug Dev. Res. 2008; 69 (6): 304-18.
  27. Nabholtz J., Buzdar A., Pollak M. et al. Anastrazole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol. 2000; 18 (8): 3758-67.
  28. Dixon J.M. Exemestane and aromatase inhibitors in the management of advanced breast cancer. Expert Opin. Pharmacother. 2004; 5: 307-16.
  29. Сметник В.П. Медицина климактерия. М.: Литтерра; 2006: 166-73.
  30. McDonnell D.P. The molecular pharmacology of SERMs. Trends Endocrinol. Metab. 1999; 10: 301-11.
  31. Jordan V.C. Selective estrogen receptor modulation: a personal perspective. Cancer Res. 2001; 61: 5683-7.
  32. Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N. Engl. J. Med. 2003; 348: 618-29.
  33. Hall J.M., McDonnell D.P. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 1999; 140: 5566-78.
  34. Bryant H. Selective estrogen receptor modulators. Rev. Endocr. Metab. Dis. 2002; 3: 231-41.
  35. Stitch S.R., Toumba J.K., Groen M.B. et al. Excretion, isolation and structure of a phenolic constituent of female urine. Nature. 1980; 287: 738-40.
  36. Adlercreutz H., Mousavi Y., Clark J., Höckersted K. et al. Dietary phytoestrogens and cancer: in vitro and in vivo studies. J. Steroid Biochem. Mol. Biol. 1992; 41: 331-7.
  37. Martin P.M., Horwitz K.B., Rujan D.S., McGuire W.L. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology. 1978; 103 (5): 1860-7.
  38. Aldercreutz H., Markkanen H., Watanabe S. Plasma concentration of phytoestrogens in Japanese men. Lancet. 1993; 342: 1209-10.
  39. Henderson B.E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal foundation award lecture. Cancer Res. 1988; 48: 246-53.
  40. Shutt D.A., Cox R.L. Steroid and phytoestrogen binding to sheep uterine receptors in vitro. J. Endocrinol. 1972; 52: 299-310.
  41. Kitts W.D., Newsome F.E., Runeckles V.C. The tstrogenic and antiestrogenic effects of coumestrol and zerananol on the immature rat uterus. Can. J. Anim. Sci. 1983; 63: 823-4.
  42. Koehler K.F. Reflections on the discovery and significance of estrogen receptor beta. Endocrinology. 2005; 26 (3): 465-78.
  43. Magee P., Rowland I. Phytoestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br. J. Nutr. 2004; 9 (4): 513-31.
  44. Danbara N., Yuri T., Tsujita-Kyutoku M., Tsukamoto R., Uehara N., Tsubura A. Enterolactone induces apoptosis and inhibits growth of human colon cancer cells both in vitro and in vivo. Anticancer Res. 2005; 25 (3B): 2269-76.
  45. Mitchell J.H., Collins A.K. Effects of soy milk supplement on plasma cholesterol levels and oxidative DNA damage in men - a pilot study. Eur. J. Nutr. 1999; 38: 143-8.
  46. Milligan J. H., Phillips B., Soulsby M. et al. Effects of dietary soy protein on stress induced brain lipid peroxidation. FASEB J. 2002; 16: Abstr. 1.379.
  47. Piontek M., Hangels K.J., Porschen R., Strohmeyer G. Anti-proliferative effect of tyrosine kinase inhibitors in epidermal growth factor-stimulated growth of human gastric cancer cells. Anticancer Res. 1993; 13: 2119-23.
  48. Boutin J.A. Tyrosine protein kinase inhibition and cancer (Minireview). Int. J. Biochem. Cell Biol. 1994; 26: 1203-26.
  49. Linford N.J., Dorsa D.M. 17-beta-Estradiol and the phytoestrogen genistein attenuate neuronal apoptosis induced by the endoplasmic reticulum calcium-ATPase inhibitor thapsigargin. Steroids. 2002; 67: 1029-40.
  50. Park D., Huang T., Frishman W.H. Phytoestrogens as cardioprotective agents. Cardiol. Rev. 2005; 13: 13-7.
  51. Ravindranath M.H., Muthugounder S., Presser N., Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv. Exp. Med. Biol. 2004; 546: 121-65.
  52. Корман Д.Б. Эндокринная терапия злокачественных опухолей. М.: Практическая медицина; 2010.
  53. Badger T.M., Gilchrist J.M., Pivik R.T., Andres A., Shankar K., Chen J.R., Ronis M.J. The health implications of soy infant formula. Am. J. Clin. Nutr. 2009; 89 (1668S-1672S40): 41.
  54. Moss G.P. Nomenclature of lignans and neolignans (IUPAC Recommendations 2000). Pure Appl. Chem. 2000; 72-P: 1493-523.
  55. Ayres D.C., Loike J.D. Lignans: chemical, biological and clinical properties. In: Chemistry & Pharmacology of Natural Products. Cambridge University Press; 1990.
  56. Heinonen S., Nurmi T., Liukkonen K., Poutanen K., Wahala K., Deyama T. et al. In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J. Agric. Food Chem. 2001; 49 (7): 3178-86.
  57. Haworth R.D. Constituents of natural phenolic resins. Nature. 1941; 147: 225-57.
  58. Борисова Ю.А., Смирнова Г.Б., Калишьян М.С., Райхлин Н.Т., Трещалина Е.М., Шпрах З.С. Результаты скрининга фитоантиэстрогена секоизоларицирезинола на эстрогензависимой аденокарциноме молочной железы Са755. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2014; 25 (1-2): 26-30.
  59. Борисова Ю.А., Смирнова Г.Б., Калишьян М.С., Райхлин Н.Т., Трещалина Е.М., Шпрах З.С. Результаты доклинического изучения нового фитоантиэстрогена секоизоларицирезинола на опухолевых моделях in vivo. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2014; 25 (3-4): 43-6.
  60. Борисова Ю.А., Шпрах З.С., Смирнова Г.Б., Орлова О.Л., Полозкова А.П., Оборотова Н.А., Трещалина Е.М. Разработка пероральной лекарственной формы секоизоларицирезинола под контролем эффективности. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2014; 25 (3-4): 51-4.
  61. Борисова Ю.А., Смирнова Г.Б., Андронова Н.В., Шпрах З.С., Калишьян М.С., Полозкова А.П., Трещалина Е.М. Результаты доклинического изучения секоизоларицирезинола на подкожных ксенографтах рака молочной железы человека. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2015; 26 (дополн.): 47-52.
  62. Borisova Yu., Smirnova G., Sedakova L., Treshchalina E., Shprakh Z. Preclinical results of the new phito-antiestrogen sekoisolaryciresinol treatment of estrogen-dependent murine tumor. In: 25th International Congress on Anti-Cancer Treatment (ICACT). Paris; 2014: 377-8.
  63. Нифантьев Н.Э., Яшунский Д.В., Меньшов В.М., Цветков Ю.Е., Цветков Д.Е. Способ выделения секоизоларицирезинола и дигидрокверцетина из древесины. Патент РФ № 2359666, 2009.
  64. Шубина И.Ж., Борисова Ю.А., Смирнова Г.Б., Киселевский М.В., Трещалина Е.М., Шпрах З.С. Диссеминация клеток аденокарциномы молочной железы Са755 в костный мозг мышей на фоне селективных модификаторов эстрогенных рецепторов (СМЭР). Российский биотерапевтический журнал. 2015; (1): 146-7.
  65. Shubina I.Zh., Borisova Yu.A., Smirnova G.B., Kiselevskiy M.V., Treshchalina E.M. Evalution of CK 19+ disseminated tumor cells in murine bone marrow after antiestrogen therapy. Hematopoies. Immunol. 2014; 1-2: 103.
  66. Борисова Ю.А., Шубина И.Ж., Смирнова Г.Б., Киселевский М.В., Трещалина Е.М. Экспериментальная оценка проэстрогенного действия секоизоларицирезинола в сравнении с тамоксифеном по экспрессии цитокератинов СК19+ в эпителиальных клетках мышей in vivo. Российский биотерапевтический журнал. 2014; (1): 68.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies